Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor
AbbVie’s landmark FDA approval for its potential blockbuster upadacitinib — the replacement for its cash cow Humira — came with a dreaded black box warning. Filgotinib, Gilead and Galapagos’ rival JAK drug, is being primed for US review but investors are nervous it too will suffer the same fate. On Friday, the companies said 52-week data from twin late-stage studies reinforced the safety, tolerability and efficacy profile of the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 63,000+ biopharma pros reading Endpoints daily — and it's free.